Statland departure lengthens FDA's vacancies list
This article was originally published in Clinica
Vacancies abound for senior positions at the FDA. The Center for Devices and Radiological Health (CDRH) is losing another top official. Dr Bernard Statland, director of the Office of Device Evaluation, is leaving effective August 23 to complete his law degree at the University of Minnesota.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.